Company news

Hansa Biopharma AB news in 2026

Hansa Biopharma AB's news releases, calls and decks from 2026, newest first.

View company

Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering

October 1, 2026

Hansa Biopharma Announces New Board Appointments

September 24, 2026

Bulletin from the Extraordinary General Meeting in Hansa Biopharma AB (publ)

September 22, 2026

Hansa Biopharma Announces Confidential Submission of Draft Registration Statement to the SEC to allow for a potential Listing of ADSs in the United States

August 21, 2026

Hansa Biopharma Reports Second Quarter and First Half Year 2026 Financial Results

July 22, 2026

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

July 1, 2026

Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for `What's Hot, What's New' Plenary at ATC 2026

June 24, 2026

Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer

June 15, 2026

Hansa Biopharma appoints Fredrik Röök as VP Business Development

June 10, 2026

Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

June 1, 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix[®] European post authorization study in kidney transplantation

May 27, 2026

Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

May 25, 2026

SERB Pharmaceuticals to acquire European and MENA rights to Idefirix from Hansa Biopharma for EUR115 million

May 20, 2026

Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

May 19, 2026

Hansa Biopharma Report First Quarter 2026 Financial Results

April 23, 2026

Hansa Biopharma to host Q1 2026 interim results conference call

April 8, 2026

Hansa Biopharma publishes 2025 Annual and Sustainability Reports

March 26, 2026

PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026

March 4, 2026

Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

February 18, 2026

Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

February 11, 2026

KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer

February 10, 2026

Hansa Biopharma has won the 2025 SwedenBIO Award

January 22, 2026

Calls in 2026

Decks in 2026